艾伯维押注PD-1/VEGF双靶点竞赛；Alnylam与Vertex公布业绩预期
AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations
生命科学资讯
生物技术与制药领域的最新动态
Vertex基因编辑疗法在儿童血液疾病治疗中取得早期目标
Vertex CRISPR therapy hits early goal in children with blood disorders
生物技术与制药领域的最新动态
AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations
Vertex CRISPR therapy hits early goal in children with blood disorders